Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
HRMY logo HRMY
Upturn stock ratingUpturn stock rating
HRMY logo

Harmony Biosciences Holdings (HRMY)

Upturn stock ratingUpturn stock rating
$36.51
Last Close (24-hour delay)
Profit since last BUY3.72%
upturn advisory
Consider higher Upturn Star rating
BUY since 20 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: HRMY (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

9 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $50.55

1 Year Target Price $50.55

Analysts Price Target For last 52 week
$50.55 Target price
52w Low $26.47
Current$36.51
52w High $41.61

Analysis of Past Performance

Type Stock
Historic Profit -31.62%
Avg. Invested days 27
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.10B USD
Price to earnings Ratio 11.78
1Y Target Price 50.55
Price to earnings Ratio 11.78
1Y Target Price 50.55
Volume (30-day avg) 9
Beta 0.84
52 Weeks Range 26.47 - 41.61
Updated Date 08/15/2025
52 Weeks Range 26.47 - 41.61
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) 3.1

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-08-05
When -
Estimate 0.72
Actual 0.92

Profitability

Profit Margin 23.42%
Operating Margin (TTM) 24.03%

Management Effectiveness

Return on Assets (TTM) 14.1%
Return on Equity (TTM) 27.58%

Valuation

Trailing PE 11.78
Forward PE 10.26
Enterprise Value 1707336262
Price to Sales(TTM) 2.72
Enterprise Value 1707336262
Price to Sales(TTM) 2.72
Enterprise Value to Revenue 2.21
Enterprise Value to EBITDA 6.44
Shares Outstanding 57532600
Shares Floating 44565903
Shares Outstanding 57532600
Shares Floating 44565903
Percent Insiders 11.07
Percent Institutions 97.34

ai summary icon Upturn AI SWOT

Harmony Biosciences Holdings

stock logo

Company Overview

overview logo History and Background

Harmony Biosciences Holdings, Inc. was founded in 2017. The company focuses on developing and commercializing therapies for rare neurological diseases, with a commitment to addressing unmet medical needs.

business area logo Core Business Areas

  • Rare Neurological Diseases: Focuses on the development and commercialization of therapies for patients living with rare neurological diseases, particularly those affecting sleep and wakefulness.

leadership logo Leadership and Structure

Harmony Biosciences is led by a management team with experience in the pharmaceutical industry. The organizational structure comprises various departments including research and development, commercial operations, medical affairs, and finance.

Top Products and Market Share

overview logo Key Offerings

  • Wakix (pitolisant): Wakix is a first-in-class histamine-3 (H3) receptor antagonist/inverse agonist approved for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy. It holds a significant market share in this segment. Competitors include Xyrem, Xywav and Sunosi.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry, particularly in the rare disease segment, is experiencing growth driven by increasing awareness, advancements in diagnostics, and regulatory support for orphan drugs.

Positioning

Harmony Biosciences has positioned itself as a leader in developing and commercializing therapies for narcolepsy and other rare neurological diseases. Its competitive advantage lies in its focus on novel mechanisms of action and unmet medical needs.

Total Addressable Market (TAM)

The narcolepsy market is estimated to be in the billions of USD. Harmony is positioned to expand in this market through drug development and approval.

Upturn SWOT Analysis

Strengths

  • Novel treatment options
  • Strong commercial performance of Wakix
  • Experienced management team
  • Focus on rare neurological diseases

Weaknesses

  • Reliance on a limited product portfolio
  • Competition from established players
  • Regulatory risks associated with drug development
  • Lack of a diverse portfolio

Opportunities

  • Expansion into new indications
  • Strategic acquisitions and partnerships
  • Geographic expansion
  • Further clinical development of pipeline candidates

Threats

  • Generic competition
  • Pricing pressures
  • Changes in healthcare regulations
  • Clinical trial failures

Competitors and Market Share

competitor logo Key Competitors

  • JAZZ
  • AVXL
  • SNDL

Competitive Landscape

Harmony Biosciences competes with other pharmaceutical companies in the narcolepsy market. The company's advantages include its novel mechanism of action with Wakix, while disadvantages include its reliance on a limited product portfolio.

Growth Trajectory and Initiatives

Historical Growth: Historical performance data needs to be pulled from a live financial terminal at the time of request. This will be available from the next model version.

Future Projections: Future Projections data needs to be pulled from a live financial terminal at the time of request. This will be available from the next model version.

Recent Initiatives: Harmony's recent initiatives include expanding the label for Wakix and pipeline advancement.

Summary

Harmony Biosciences is a pharmaceutical company with a focus on rare neurological diseases. Wakix sales continue to grow, establishing their presence in the narcolepsy market. Future growth depends on pipeline development and competition in an established market will provide challenges. They must look out for potential generic competition and regulatory hurdles.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings
  • Market Research Reports
  • Analyst Reports

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Market share data are estimates and may vary. Actual financial results may differ.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Harmony Biosciences Holdings

Exchange NASDAQ
Headquaters Plymouth Meeting, PA, United States
IPO Launch date 2020-08-19
President, CEO & Director Dr. Jeffrey M. Dayno M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 268
Full time employees 268

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; and EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies (DEE). The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.